Atherosclerosis in patients with cyanotic congenital heart disease

Circulation Journal

Volumn 74, Issue 7, 2010, Pages 1436-1441

  Duffels, Mariëlle G J ^a   Mulder, Karlijn M ^a   Trip, Mieke D ^a   de Groot, Erik ^a   Groot, John ^a   van Dijk, Arie P J ^b   Hoendermis, Elke S ^c   Daliento, Luciano ^e   Zwinderman, Aeiko H ^a   Berger, Rolf M F ^c   Mulder, Barbara J M ^a,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Atherosclerosis; Carotid intima media thickness; Cyanotic congenital heart disease; Eisenmenger syndrome

Indexed keywords

BILIRUBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; CHOLESTEROL;

ADULT; ARTERIAL OXYGEN SATURATION; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BILIRUBIN BLOOD LEVEL; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYANOTIC HEART DISEASE; DIASTOLIC BLOOD PRESSURE; EISENMENGER COMPLEX; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; ADOLESCENT; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; CYANOSIS; HEART DISEASES; MIDDLE AGED; PATHOLOGY; RISK FACTOR; THROMBOCYTE;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; BILIRUBIN; BLOOD PLATELETS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CHOLESTEROL; CYANOSIS; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 77954504889     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0858     Document Type: Article

References (37)

1. Perloff JK. The coronary circulation in cyanotic congenital heart disease. Int J Cardiol 2004; 97(Suppl 1): 79-86.
2. Fyfe A, Perloff JK, Niwa K, Child JS, Miner PD. Cyanotic congenital heart disease and coronary artery atherogenesis. Am J Cardiol 2005; 96: 283-290.
3. Duffels MG, Engelfriet PM, Berger RM, van Loon RL, Hoendermis E, Vriend JW, et al. Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120: 198-204.
4. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958; 46: 755-762.
5. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, et al. Eisenmenger syndrome: Factors relating to deterioration and death. Eur Heart J 1998; 19: 1845-1855.
6. Duffels MGJ, Berger RMF, Bresser P, de Bruin-Bon HACM, Hoendermis E, Bouma BJ, et al. Applicability of bosentan in Dutch patients with Eisenmenger syndrome: Preliminary results on safety and exercise capacity. Neth Heart J 2006; 14: 165-170.
7. van Loon RL, Hoendermis ES, Duffels MG, Vonk-Noordegraaf A, Mulder BJ, Hillege HL, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: Does the beneficial effect persist? Am Heart J 2007; 154: 776-782.
8. Perloff JK. Systemic complications of cyanosis in adults with congenital heart disease: Hematologic derangements, renal function, and urate metabolism. Cardiol Clin 1993; 11: 689-699.
9. Oechslin E. Hematological management of the cyanotic adult with congenital heart disease. Int J Cardiol 2004; 97(Suppl 1): 109-115.
10. Lill MC, Perloff JK, Child JS. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. Am J Cardiol 2006; 98: 254-258.
11. Groot de E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004; 109: III-33-III-38.
12. Bots ML, Baldassarre D, Simon A, de Groot E, O'Leary DH, Riley W, et al. Carotid intima-media thickness and coronary atherosclerosis: Weak or strong relations? Eur Heart J 2007; 28: 398-406.
13. Kastelein JJ, Wiegman A, de Groot E. Surrogate markers of atherosclerosis: Impact of statins. Atheroscler Suppl 2003; 4: 31-36.
14. Van der Velde ET, Vriend JW, Mannens MM, Uiterwaal CS, Brand R, Mulder BJ. CONCOR, an initiative towards a national registry and DNA-bank of patients with congenital heart disease in the Netherlands: Rationale, design, and first results. Eur J Epidemiol 2005; 20: 549-557.
15. Han TH, Perloff JK, Liao JC. Nitric oxide metabolism in adults with cyanotic congenital heart disease. Am J Cardiol 2007; 99: 691-695.
16. Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound: ARIC Investigators. Stroke 1993; 24: 1297-1304.
17. Juonala M, Kahonen M, Laitinen T, Hutri-Kahonen N, Jokinen E, Taittonen L, et al. Effect of age and sex on carotid intima-media thickness, elasticity and brachial endothelial function in healthy adults: The Cardiovascular Risk in Young Finns Study. Eur Heart J 2008; 29: 1198-1206.
18. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized controlled clinical trial. Ann Intern Med 1996; 124: 548-556.
19. Rosove MH, Perloff JK, Hocking WG, Child JS, Canobbio MM, Skorton DJ. Chronic hypoxaemia and decompensated erythrocyto-sis in cyanotic congenital heart disease. Lancet 1986; 2: 313-315.
20. Madhavan M, Wattigney WA, Srinivasan SR, Berenson GS. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis 1997; 131: 107-113.
21. Rich MW. Uric acid: Is it a risk factor for cardiovascular disease? Am J Cardiol 2000; 85: 1018-1021.
22. Wallace RB, Hunninghake DB, Reiland S, Barrett-Connor E, Mackenthun A, Hoover J, et al. Alterations of plasma high-density lipoprotein cholesterol levels associated with consumption of selected medications: The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62: IV-77-IV-82.
23. Madu EC, Reddy RC, Madu AN, Anyaogu C, Harris T, Fraker TD Jr. The effects of antihypertensive agents on serum lipids. Am J Med Sci 1996; 312: 76-84.
24. Norozi K, Buchhorn R, Wessel A, Bahlmann J, Raab B, Geyer S, et al. Beta-blockade does not alter plasma cytokine concentrations and ventricular function in young adults with right ventricular dysfunction secondary to operated congenital heart disease. Circ J 2008; 72: 747-752.
25. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105: 290-292.
26. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305: 869-872.
27. Levine RF, Eldor A, Shoff PK, Kirwin S, Tenza D, Cramer EM. Circulating megakaryocytes: Delivery of large numbers of intact, mature megakaryocytes to the lungs. Eur J Haematol 1993; 51: 233-246.
28. Geddis AE, Kaushansky K. Immunology. The root of platelet production. Science 2007; 317: 1689-1691.
29. Kajimoto H, Nakazawa M, Murasaki K, Mori Y, Tanoue K, Kasanuki H, et al. Increased thrombogenesity in patients with cya-notic congenital heart disease. Circ J 2007; 71: 948-953.
30. Kajimoto H, Nakazawa M, Murasaki K, Hagiwara N, Nakanishi T. Increased P-selectin expression on platelets and decreased plasma thrombomodulin in Fontan patients. Circ J 2009; 73: 1705-1710.
31. Horigome H, Murakami T, Isobe T, Nagasawa T, Matsui A. Soluble P-selectin and thrombomodulin-protein C-protein S pathway in cyanotic congenital heart disease with secondary erythrocytosis. Thromb Res 2003; 112: 223-227.
32. DeFilippis AP, Law K, Curtin S, Eckman JR. Blood is thicker than water: The management of hyperviscosity in adults with cyanotic heart disease. Cardiol Rev 2007; 15: 31-34.
33. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: Hematologic management. Ann Intern Med 1988; 109: 406-413.
34. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thilen U, et al. The spectrum of adult congenital heart disease in Europe: Morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26: 2325-2333.
35. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28: 768-772.
36. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cya-notic congenital heart disease. Circulation 1993; 87: 1954-1959.
37. Juonala M, Kahonen M, Laitinen T, Hutri-Kahonen N, Jokinen E, Taittonen L, et al. Effect of age and sex on carotid intima-media thickness, elasticity and brachial endothelial function in healthy adults: The Cardiovascular Risk in Young Finns Study. Eur Heart J 2008; 29: 1198-1206.